跳至主要内容
临床试验/JPRN-jRCT2080221542
JPRN-jRCT2080221542已完成3 期

CS-747S PhaseIII trial -Non-inferiority study of CS-747S versus clopidogrel bisulfate in patients with ischemic cerebrovascular accident.

DAIICHISANKYO Co.,Ltd.0 个研究点目标入组 3,753 人开始时间: 2011年8月11日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
3,753

研究概览

简要总结

The non-inferiority of CS-747S to clopidogrel for the prevention of ischemic stroke, myocardial infarction, and other vascular death was not confirmed in patients with non-cardioembolic stroke. The incidences rate of cerebro-cardiovascular events and other efficacy events were generally similar to clopidogrel. The incidence rate of adverse events and bleeding events were comparable between CS-747S and clopidogrel, suggesting that there are no significant safety issues with CS-747S.

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 <= 74age old(—)
性别
All

入选标准

  • Patients with cerebral infarction that caused the last attack.
  • -The last attack : between 1 and 26 weeks prior to informed consent.
  • -Body weight: over 50 kg

排除标准

  • -Patients who need the dual antiplatelet therapy.
  • -History of intracerebral hemorrhage.
  • -Bleeding disorder or bleeding diathesis.
  • -Patients with poorly-controlled blood pressure.
  • -Severe hepatic disorder or kidney disturbance.

研究者

发起方
DAIICHISANKYO Co.,Ltd.

相似试验